News & Updates

Show Multimedia Only

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025 by

Compared with tirzepatide, subcutaneous semaglutide 2.4 mg is associated with a 57 percent lower risk of revised 3-point major adverse cardiovascular events (3P-MACE; defined as MI, stroke, and all-cause mortality [instead of cardiovascular-related death]) in a population similar to the SELECT trial — patients with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD) but no history of diabetes, according to results of the real-world STEER trial presented at the European Society of Cardiology (ESC) Congress 2025.

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

The use of direct oral anticoagulants (DOACs) appears to be safer than warfarin for patients with nonvalvular atrial fibrillation (AF) and liver cirrhosis (LC), suggests a study. This is particularly true to reducing the risk of major bleeding in those with Child-Pugh class A disease.

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

Butter vs margarine: Which oil supports cardiometabolic health?

30 Sep 2025

About a teaspoon (5 g) of butter a day can help improve cardiometabolic health outcomes and reduce the risk of type 2 diabetes (T2D), reports a recent study. In contrast, margarine may elevate the risk of both cardiovascular disease (CVD) and T2D.

Butter vs margarine: Which oil supports cardiometabolic health?

30 Sep 2025

New HTN guidelines advocate for early Tx

30 Sep 2025 by

The new ACC/AHA* hypertension guidelines reinforce previous recommendations to lower blood pressure (BP) early and aggressively, with a greater emphasis on lifestyle interventions, the link between BP and cognitive function, and pregnancy.

New HTN guidelines advocate for early Tx

30 Sep 2025

Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients

29 Sep 2025 by

Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.

Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients

29 Sep 2025

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

28 Sep 2025 by

Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

28 Sep 2025

No increase in hypertension risk with lifetime cannabis use

27 Sep 2025

Cumulative lifetime use of cannabis does not appear to raise the risk of developing hypertension, as shown in the study.

No increase in hypertension risk with lifetime cannabis use

27 Sep 2025

Marital failure linked to subsequent heart failure

26 Sep 2025

Experiencing a loss of stable spousal relationships, particularly recent marital failure, appears to increase susceptibility to heart failure, according to a large study.

Marital failure linked to subsequent heart failure

26 Sep 2025

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025 by

A 57-year-old male lorry driver, who was an ex-chronic smoker and had underlying chronic diseases, was hospitalized due to a 3-day history of fever, cough, and shortness of breath in April 2025.

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025

Menopausal hormone therapy poses cardiac risk for older women

24 Sep 2025 by

Hormone therapy for vasomotor symptoms (VMS) appears to raise the risk of atherosclerotic cardiovascular disease (ASCVD) for women exposed to the treatment later in life, according to a secondary analysis of two Women’s Health Initiative (WHI) trials.

Menopausal hormone therapy poses cardiac risk for older women

24 Sep 2025

News & Updates

Showing Cardiology articles

Showing

Specialty:

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

Butter vs margarine: Which oil supports cardiometabolic health?

Butter vs margarine: Which oil supports cardiometabolic health?

New HTN guidelines advocate for early Tx

New HTN guidelines advocate for early Tx

Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients

Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

Semaglutide, dulaglutide help prevent cognitive decline in HF patients

No increase in hypertension risk with lifetime cannabis use

No increase in hypertension risk with lifetime cannabis use

Marital failure linked to subsequent heart failure

Marital failure linked to subsequent heart failure

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Menopausal hormone therapy poses cardiac risk for older women

Menopausal hormone therapy poses cardiac risk for older women